Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.55 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.55 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785797 | 1.00 | MAPT (0.55) | MAPTLMNARECQLPLIN1PLIN5 | |
| SCHEMBL2954318 | 0.81 | MAPT (0.70) | MAPTLMNARECQLPLIN1PLIN5 | |
| SCHEMBL2954324 | 0.81 | MAPT (0.70) | MAPTLMNARECQLPLIN1PLIN5 | |
| SCHEMBL11073619 | 0.81 | MAPT (0.70) | MAPTLMNARECQLPLIN1PLIN5 | |
| SCHEMBL28515948 | 0.81 | MAPT (0.59) | MAPTMAOBCYP1B1ALDH1A1TDP1 | |
| SCHEMBL16762593 | 0.79 | ALDH1A1 (0.69) | MAPTLMNAMAOBCYP1B1ALDH1A1 | |
| SCHEMBL7147542 | 0.76 | ALDH1A1 (0.67) | MAPTLMNARECQLPLIN1PLIN5 | |
| SCHEMBL7600099 | 0.75 | MAPT (0.61) | MAPTLMNARECQLPLIN1PLIN5 | |
| SCHEMBL21429061 | 0.75 | MAPT (0.61) | MAPTLMNARECQLPLIN1PLIN5 | |
| SCHEMBL11883016 | 0.75 | MAPT (0.61) | MAPTLMNARECQLPLIN1PLIN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505765-B2 | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150203499-A1 | 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT | ACLARIS THERAPEUTICS, INC. | 2015-07-23 | — | — | US | disclosed |
| WO-2014018888-A1 | 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-7858349-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010127381-A1 | DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS | JAMES COOK UNIVERSITY (AU) | 2010-11-11 | — | — | WO | disclosed |
| US-20090088454-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-04-02 | — | — | US | disclosed |
| US-7427496-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-23 | — | — | US | disclosed |
| US-20060183772-A1 | To inhibit tumor growth in an animal; to induce apoptosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203499-A1 | 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT | MAP3K6, MAP3K20, MAP3K4 | MAPT 225/4885LMNA 2687/4885RECQL 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.